Cardiovascular Drugs and Therapy最新文献

Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis.

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-24 DOI: 10.1007/s10557-024-07659-w

Bozhi Ye, Xueli Cai, Xiaohe Liang, Yunxuan Chen, Shanshan Dai, Zhuqi Huang, Weijian Huang, Lei Zhang, Zixuan Wang, Jincheng Xing, Xianhui Lai, Zhouqing Huang, Zhuyin Jia

{"title":"Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis.","authors":"Bozhi Ye, Xueli Cai, Xiaohe Liang, Yunxuan Chen, Shanshan Dai, Zhuqi Huang, Weijian Huang, Lei Zhang, Zixuan Wang, Jincheng Xing, Xianhui Lai, Zhouqing Huang, Zhuyin Jia","doi":"10.1007/s10557-024-07659-w","DOIUrl":"https://doi.org/10.1007/s10557-024-07659-w","url":null,"abstract":"Purpose: Inflammatory responses induced by NLRP3 inflammasome contribute to the progression of atherosclerosis. This study seeks to investigate the effect of emodin on the NLRP3 inflammasome in atherogenesis and to probe the underlying mechanism.Methods: ApoE-knockout (ApoE-/-) mice were treated with a high-fat diet (HFD) for 12 weeks and intragastrically with emodin for 6 weeks. Human mononuclear cell line THP-1 was pretreated with emodin or signaling pathway inhibitors and induced into macrophages using phorbol 12-myristate 13-acetate (PMA) for 48 h. The NLRP3-mediated inflammatory response was studied both in vivo and in vitro. The level of the inflammation was detected by western blot, real-time PCR analysis, and ELISA.Results: Emodin attenuated atherosclerotic lesions in HFD-treated ApoE-/- mice. Emodin dramatically decreased the expression of NLRP3, GSDMD, IL-1β, and IL-18 in HFD-treated ApoE-/- mice and PMA-induced macrophages. Moreover, emodin significantly hindered the activation of nuclear factor kappa-B (NF-κB) by inhibiting the formation of the TLR4/MyD88 complex in PMA-induced macrophages.Conclusion: Our data demonstrate that emodin can inhibit the development of atherosclerotic plaques by alleviating NLRP3/GSDMD-induced inflammation through repressing the TLR4/MyD88/NF-κB signaling pathway in macrophages. This finding suggests that emodin can be a potential candidate for the treatment of atherosclerosis.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming Hypertension Treatment: Zilebesiran's Possible Impact. 改变高血压治疗：Zilebesiran可能产生的影响。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-20 DOI: 10.1007/s10557-024-07656-z

Muhammad Owais, Arisha Akhtar, Priyadarshini Bhattacharjee

引用次数: 0

Quercetin Alleviates Cardiac Fibrosis via Regulating the SIRT3 Signaling Pathway. 槲皮素通过调节 SIRT3 信号通路缓解心脏纤维化

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-16 DOI: 10.1007/s10557-024-07658-x

Da-Wei Lin, Yi-Wen Jiang, Chen Wu, Hao Zhang, Ying-Ze Li, Yao-Sheng Wang

{"title":"Quercetin Alleviates Cardiac Fibrosis via Regulating the SIRT3 Signaling Pathway.","authors":"Da-Wei Lin, Yi-Wen Jiang, Chen Wu, Hao Zhang, Ying-Ze Li, Yao-Sheng Wang","doi":"10.1007/s10557-024-07658-x","DOIUrl":"10.1007/s10557-024-07658-x","url":null,"abstract":"Purpose: Cardiovascular diseases, exacerbated by cardiac fibrosis, are the leading causes of mortality. We aimed to determine the role of quercetin (QU) in cardiac fibrosis and the underlying mechanism.Methods: In this study, 8-week-old mice were subjected to either transverse aortic constriction (TAC) or sham surgery, then they were administered QU or saline. Thereafter, cardiac function and cardiac hypertrophy were accessed. In vitro, cardiac fibroblasts (CFs) were treated with angiotensin II (Ang II) with or without QU. Western blot, qPCR, EdU incorporation assay, and immunofluorescence staining analysis were used to investigate the molecular and cellular features.Results: For the TAC mouse model, cardiac fibrosis was alleviated by QU. The study revealed that the trans-differentiation and proliferation of CFs promoted by Ang II would be reversed by QU in vitro. Mechanistically, QU exerted the anti-fibrotic effect by regulating the SIRT3/TGF-β/Smad3 signaling pathway.Conclusion: Quercetin protects against cardiac fibrosis by mediating the SIRT3 signaling pathway.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastroprotection in Heart Failure and Outcomes: A Systematic Review of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists. 心力衰竭患者的胃肠保护与预后：质子泵抑制剂和组胺-2 受体拮抗剂的系统性回顾。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-14 DOI: 10.1007/s10557-024-07660-3

Mustafa Eray Kilic, Mehmet Birhan Yilmaz

{"title":"Gastroprotection in Heart Failure and Outcomes: A Systematic Review of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists.","authors":"Mustafa Eray Kilic, Mehmet Birhan Yilmaz","doi":"10.1007/s10557-024-07660-3","DOIUrl":"https://doi.org/10.1007/s10557-024-07660-3","url":null,"abstract":"Purpose: The management of heart failure (HF) frequently includes gastroprotection via proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs). This systematic review evaluates their impact on HF outcomes, including exacerbation, hospitalization, mortality, and major adverse cardiac events (MACE).Methods: In accordance with PRISMA guidelines, a complete search across databases such as PubMed/Medline, Scopus, and Web of Science was conducted until December 10, 2023. The inclusion criteria covered research on adult patients with HF that focused on the effects of PPI and H2RA usage. The risk of bias was determined via the Newcastle-Ottawa Scale (NOS), and data were synthesized quantitatively.Results: Eleven studies encompassing 996,498 participants were analyzed. The data is not consistent across all research; however, some have suggested that PPI use may be linked to an increased risk of cardiovascular illnesses and heart failure aggravation. Conversely, H2RAs appeared to offer potential benefits in certain high-risk groups, potentially reducing all-cause and cardiovascular mortality. However, the limitations of the available studies should be taken into consideration when interpreting these findings.Conclusion: The review suggests that there may be differences in the impact of PPIs and H2RAs on HF outcomes. While some evidence indicates that PPIs may be linked to increased risks in HF patients, and H2RAs may offer potential benefits, these findings are not definitive and should be interpreted with caution. Further research is necessary to clarify these associations and guide clinical practice.Registration: PROSPERO CRD42023491752.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Clinical Use of Lansoprazole and the Risk of Coronary Heart Disease: A Nationwide Pharmacoepidemiological Cohort Study. 临床使用兰索拉唑与冠心病风险之间的关系：全国药物流行病学队列研究》。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-13 DOI: 10.1007/s10557-024-07643-4

Ming-Hsun Lin, Wen-Tung Wu, Yong-Chen Chen, Wu-Chien Chien, Tsung-Kun Lin, Yu-Ching Chou, Po-Shun Hsu, Chien-An Sun

{"title":"Association Between Clinical Use of Lansoprazole and the Risk of Coronary Heart Disease: A Nationwide Pharmacoepidemiological Cohort Study.","authors":"Ming-Hsun Lin, Wen-Tung Wu, Yong-Chen Chen, Wu-Chien Chien, Tsung-Kun Lin, Yu-Ching Chou, Po-Shun Hsu, Chien-An Sun","doi":"10.1007/s10557-024-07643-4","DOIUrl":"https://doi.org/10.1007/s10557-024-07643-4","url":null,"abstract":"Purpose: Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Lansoprazole, a PPI, has been recognized for its potential effects of improving insulin resistance, reduction of oxidative stress, and improvement in atherosclerosis through peroxisome proliferator-activated receptor gamma (PPARγ) induction. This study aims to investigate whether lansoprazole poses a distinct risk of coronary heart disease (CHD) compared to other PPIs.Methods: A retrospective cohort study utilized data from the National Health Insurance Research Database in Taiwan spanning from 2000 to 2013. The exposed cohort included 1666 patients with lansoprazole use, while the comparison cohort comprised 6664 patients using other PPIs. The primary outcome was incident CHD. Cox regression models were employed to assess the association between lansoprazole use and CHD risk, presenting hazard ratios (HRs) and 95% confidence intervals (CIs).Results: Patients prescribed lansoprazole demonstrated a significantly reduced risk of CHD compared to those undergoing other PPI treatments in individuals without a history of CHD. Lansoprazole users exhibited a 25% lower risk of developing CHD compared to other PPI users (adjusted HR 0.75; 95% CI 0.65-0.87). Intriguingly, this inverse association between lansoprazole use and CHD risk was consistent across genders and various age groups.Conclusion: This study suggests that lansoprazole is associated with a decreased risk of CHD in comparison to other PPIs in patients without a history of CHD. Further research is warranted to elucidate the clinical implications of these findings.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should We Recommend Vitamin K2 Supplement to Prevent Coronary Artery Calcification for Patients Receiving Statins and/or Warfarin?

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-13 DOI: 10.1007/s10557-024-07661-2

Allan Jean Zhang, Christie M Ballantyne, Yochai Birnbaum

{"title":"Should We Recommend Vitamin K2 Supplement to Prevent Coronary Artery Calcification for Patients Receiving Statins and/or Warfarin?","authors":"Allan Jean Zhang, Christie M Ballantyne, Yochai Birnbaum","doi":"10.1007/s10557-024-07661-2","DOIUrl":"https://doi.org/10.1007/s10557-024-07661-2","url":null,"abstract":"Several reports suggest that in animal models, as well as in the clinical setting, long-term warfarin use increases coronary artery calcifications. The same has been reported for statins prescribed for patients at risk or with established atherosclerosis. Coronary calcifications are considered a risk marker for further cardiovascular events. However, numerous clinical trials have established that statins reduce the risk for cardiovascular events. Warfarin also has been shown to reduce the risk of cardiovascular events, including re-infarction. It has been suggested that the increase in coronary calcification can be viewed as a marker of stabilization of the coronary plaque in such patients. Warfarin inhibits the activation of Vitamin K epoxide reductase complex 1 (VKORC1), which blocks the regeneration of reduced vitamin K1 and K2. Vitamin K1 is predominantly localized to the liver, serving to carboxylate clotting factors. Vitamin K2 travels through systemic circulation, with significant and wide-ranging effects. Several studies using animal models of atherosclerosis have shown that vitamin K2 supplement can attenuate the progression of atherosclerosis, as well as coronary calcification. Clinical studies supporting this effect in patients are lacking. Yet, there is an increase in the use of over-the-counter vitamin K2 supplements, and several manuscripts recommended its use in patients receiving long-term warfarin to attenuate coronary calcification. However, it is unclear if this occurs in patients with atherosclerosis receiving warfarin or statins and if attenuating coronary calcification has beneficial or detrimental effects on cardiovascular outcomes.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-12 DOI: 10.1007/s10557-024-07657-y

Livia Caroline Lucca, Laura Gasparin Scalco, Fernando Fornari

引用次数: 0

Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy.

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-10 DOI: 10.1007/s10557-024-07652-3

Dorsa Alijanzadeh, Shahrzad Moghim, Paniz Zarand, Mohammad Ali Akbarzadeh, Yasaman Zarinfar, Isa Khaheshi

{"title":"Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy.","authors":"Dorsa Alijanzadeh, Shahrzad Moghim, Paniz Zarand, Mohammad Ali Akbarzadeh, Yasaman Zarinfar, Isa Khaheshi","doi":"10.1007/s10557-024-07652-3","DOIUrl":"https://doi.org/10.1007/s10557-024-07652-3","url":null,"abstract":"Background: Ivabradine has been identified as a funny current (If) inhibitor in the sinoatrial node (SAN) and is considered an advocated therapeutic agent in chronic heart failure and stable angina. This therapeutic agent has shown positive benefits in maintaining a reduction in heart rate while sustaining hemodynamic stability. Its clinical application is still evolving and the mechanism of action is becoming clearer daily. The use of this agent to manage atrial fibrillation (AF) has recently been brought under discussion. This study summarizes the mechanism of action of ivabradine and current evidence about the risk of new-onset AF and rate-lowering potential as a therapeutic option in patients suffering from AF.Methods: This review synthesizes findings from preclinical studies, case reports, and clinical trials that assess ivabradine's efficacy in controlling heart rate and its association with new-onset AF.Results: Studies have shown that this medication may be beneficial in ventricular rate reduction in patients intolerant of first-line AF therapeutic options, including non-dihydropyridine calcium channel blockers and β-blockers. However, it is important to state that ivabradine-treated patients with cardiovascular diseases demonstrated an increased risk for new-onset AF compared with those patients who did not receive it.Conclusion: While ivabradine demonstrates promise as a therapeutic option for rate control in patients with AF, its use is accompanied by a notable risk of new-onset AF. Further studies should focus on optimal dosing strategies and long-term outcomes of ivabradine treatment in AF management.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytochrome P450-derived Epoxyeicosatrienoic Acid, the Regulation of Cardiovascular-related Diseases, and the Implication for Pulmonary Hypertension.

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-09 DOI: 10.1007/s10557-024-07655-0

Run Lan, Meng-Jie Zhang, Ke Liu, Fang-Fang Meng, Xiao-He Xu, Chen-Chen Wang, Meng-Qi Zhang, Yi Yan, Jie-Jian Kou, Lu-Ling Zhao, Yang-Yang He, Hong-Da Zhang

{"title":"Cytochrome P450-derived Epoxyeicosatrienoic Acid, the Regulation of Cardiovascular-related Diseases, and the Implication for Pulmonary Hypertension.","authors":"Run Lan, Meng-Jie Zhang, Ke Liu, Fang-Fang Meng, Xiao-He Xu, Chen-Chen Wang, Meng-Qi Zhang, Yi Yan, Jie-Jian Kou, Lu-Ling Zhao, Yang-Yang He, Hong-Da Zhang","doi":"10.1007/s10557-024-07655-0","DOIUrl":"https://doi.org/10.1007/s10557-024-07655-0","url":null,"abstract":"Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid (AA) into biologically active epoxyeicosatrienoic acids (EETs), forming a pivotal metabolic pathway (AA-CYP-EETs-soluble epoxide hydrolase-dihydroxyeicosatrienoic acids) implicated in the progression of various disorders. Inflammation is a key contributor to the onset and progression of numerous systemic diseases, and EETs play a significant role in mitigating inflammation. Extensive research highlights the cardiovascular protective effects of EETs, which include vasodilation, anti-hypertensive, and anti-atherosclerotic properties. Interestingly, the relatively less-explored third metabolic pathway of AA exhibits both pro-proliferative and anti-apoptotic effects in endothelial cells and smooth muscle cells. Recent studies have shown elevated levels of EETs catalyzed by CYP epoxygenases in human tumors, promoting tumor progression and metastasis-phenomena closely related to the disease progression in pulmonary hypertension (PH). This review explores the current understanding of the regulatory functions of CYP-derived EETs in cardiovascular diseases and seeks to elucidate their potential implications in PH. Ultimately, understanding the multifaceted roles of EETs may help identify novel therapeutic targets for both cardiovascular diseases and PH.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ferroptosis in Cardiovascular Diseases and Ferroptosis-Related Intervention Approaches.

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2024-12-06 DOI: 10.1007/s10557-024-07642-5

Xianpeng Zhou, Hao Wang, Biao Yan, Xinwen Nie, Qingjie Chen, Xiaosong Yang, Min Lei, Xiying Guo, Changhan Ouyang, Zhanhong Ren

{"title":"Ferroptosis in Cardiovascular Diseases and Ferroptosis-Related Intervention Approaches.","authors":"Xianpeng Zhou, Hao Wang, Biao Yan, Xinwen Nie, Qingjie Chen, Xiaosong Yang, Min Lei, Xiying Guo, Changhan Ouyang, Zhanhong Ren","doi":"10.1007/s10557-024-07642-5","DOIUrl":"https://doi.org/10.1007/s10557-024-07642-5","url":null,"abstract":"Objective: Cardiovascular diseases (CVDs) are major public health problems that threaten the lives and health of individuals. The article has reviewed recent progresses about ferroptosis and ferroptosis-related intervention approaches for the treatment of CVDs and provided more references and strategies for targeting ferroptosis to prevent and treat CVDs.Methods: A comprehensive review was conducted using the literature researches.Results and discussion: Many ferroptosis-targeted compounds and ferroptosis-related genes may be prospective targets for treating CVDs and our review provides a solid foundation for further studies about the detailed pathological mechanisms of CVDs.Conclusion: There are challenges and limitations about the translation of ferroptosis-targeted potential therapies from experimental research to clinical practice. It warrants further exploration to pursure safer and more effective ferroptosis-targeted thereapeutic approaches for CVDs.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0